Clinical Trial Update: A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A randomized Phase II trial evaluating oral thalidomide in men with hormone-refractory prostate cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostatic Neoplasm | Phase 2 | Status: COMPLETED